Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
DRTX [NASD]
Durata Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.76 Insider Own58.07% Shs Outstand26.79M Perf Week0.17%
Market Cap647.25M Forward P/E- EPS next Y-1.37 Insider Trans0.14% Shs Float9.76M Perf Month2.20%
Income- PEG- EPS next Q-0.80 Inst Own33.80% Short Float5.89% Perf Quarter50.81%
Sales10.08M P/S64.21 EPS this Y-15.60% Inst Trans-17.34% Short Ratio0.90 Perf Half Y44.50%
Book/sh-0.60 P/B- EPS next Y53.90% ROA- Target Price23.00 Perf Year111.00%
Cash/sh- P/C- EPS next 5Y26.00% ROE- 52W Range9.94 - 24.33 Perf YTD88.90%
Dividend- P/FCF- EPS past 5Y0.00% ROI- 52W High-0.70% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low143.06% ATR0.24
Employees206 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)72.06 Volatility0.90% 0.88%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.73 Prev Close24.16
ShortableNo LT Debt/Eq- EarningsNov 03 BMO Payout- Avg Volume636.77K Price24.16
Recom2.70 SMA200.80% SMA5020.61% SMA20050.73% Volume0 Change0.00%
Oct-15-14Downgrade ROTH Capital Buy → Neutral $23
Jun-20-14Initiated Gabelli & Co Hold
May-27-14Reiterated RBC Capital Mkts Outperform $19 → $23
May-23-14Initiated MLV & Co Buy $21
Apr-09-14Initiated Summer Street Research Buy $22
Apr-01-14Reiterated RBC Capital Mkts Outperform $17 → $19
Nov-18-14 06:17AM  ArQule (ARQL) Shows Strength: Stock Adds 6 % in Session Zacks
06:13AM  Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% Zacks
Nov-17-14 03:26PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisiti EDGAR Online
08:00AM  Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer PR Newswire
Nov-15-14 01:04PM  DURATA THERAPEUTICS, INC. Financials EDGAR Online Financials
Nov-13-14 04:46PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Nov-07-14 07:50AM  DURATA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Oct-31-14 04:15PM  Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata PR Newswire
Oct-29-14 02:02PM  SHAREHOLDER ALERT: Brower Piven Announces Class Action Lawsuit in Connection With the Sale of Durata Therapeutics, Inc. -- DRTX GlobeNewswire
Oct-15-14 05:36AM  Durata Therapeutics downgraded by ROTH Capital Briefing.com
Oct-14-14 12:36PM  INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis Business Wire
Oct-11-14 07:05AM  SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in Connection with the Sale of the Company Business Wire
Oct-10-14 06:45PM  DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) Over the Proposed Sale of the Company to Actavis plc (ACT) PR Newswire
05:31PM  DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
05:25PM  SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
01:34PM  Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM) GlobeNewswire
Oct-09-14 08:20PM  Harwood Feffer LLP Announces Investigation of Durata Therapeutics, Inc. PR Newswire
04:40PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Oct-07-14 06:29PM  Lifshitz & Miller Law Firm Announces Investigation of Altair Nanotechnologies, Inc., CareFusion, Durata Therapeutics, Inc., Einstein Noah Restaurant Group, Inc., Millennial Media, Inc., and Move, Inc. PR Newswire
04:42PM  Actavis in Acquisition Mode, Durata Deal to Boost Portfolio Zacks
04:34PM  INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata Therapeutics Inc. Regarding the Fairness of the Sale of the Company to Actavis - ACT PR Newswire
03:39PM  DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
10:45AM  Ryan & Maniskas, LLP Announces Investigation of Durata Therapeutics, Inc. PR Newswire
10:43AM  INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis -- DRTX PR Newswire
09:29AM  Stock Market News for October 07, 2014 Zacks
Oct-06-14 07:15PM  DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics Inc. (DRTX) over the Proposed Sale of the Company to Actavis plc (ACT) Business Wire +74.64%
06:45PM  Actavis expands antibiotics Investor's Business Daily
06:43PM  INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata Therapeutics Inc. Regarding the Fairness of the Sale of the Company to Actavis Business Wire
06:30PM  SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
04:54PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta EDGAR Online
01:29PM  Nasdaq stocks posting largest percentage increases AP
01:22PM  Glancy Binkow & Goldberg LLP is Investigating Durata Therapeutics, Inc. Board of Directors Business Wire
12:46PM  Midday movers: Chimerix, H&R Block, McDonald's & More at CNBC
12:34PM  [$$] Actavis to Buy Antibiotic Maker at The Wall Street Journal
12:03PM  INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata Therapeutics Inc. Concerning the Fairness of the Sale of the Company to Actavis Business Wire
11:51AM  DURATA THERAPEUTICS SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Acquisition by Actavis Business Wire
11:35AM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc DRTX Business Wire
11:34AM  DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
10:58AM  Actavis Expands Antibiotics Presence With Durata Buy at Investor's Business Daily
10:20AM  Why Durata Therapeutics (DRTX) Stock Hit a One-Year High Today at TheStreet
09:33AM  What We're Trading Yahoo Finance Blogs
09:32AM  DURATA SHAREHOLDER ALERT: Johnson & Weaver, LLP Launches an Investigation into the Proposed Sale of Durata Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional Information Business Wire
08:44AM  Actavis agrees to acquire Durata Therapeutics at MarketWatch
08:34AM  Actavis buying Durata Therapeutics for $616.4 AP
08:32AM  Actavis to Buy Durata for $675 Million for Antibiotic at Bloomberg
08:00AM  Actavis to Acquire Durata Therapeutics, Inc. PR Newswire
06:44AM  Durata Therapeutics, Inc. (DRTX) Surges: Stock Rises 17.3% Zacks
Oct-03-14 08:00AM  FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia GlobeNewswire +17.33%
Oct-02-14 09:00AM  Durata Therapeutics to Present Five Posters at IDWeek 2014 GlobeNewswire
Sep-09-14 09:00AM  Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) GlobeNewswire
Sep-03-14 09:00AM  Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) GlobeNewswire
Aug-28-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -5.88%
09:09AM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Aug-26-14 05:00PM  Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors GlobeNewswire
Aug-22-14 05:01PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ EDGAR Online
Aug-19-14 07:00AM  5 Stocks Moving on Unusual Volume at TheStreet
Aug-13-14 06:53AM  What Makes Durata Therapeutics (DRTX) a Strong Sell? Zacks +5.45%
Aug-07-14 12:53PM  Device maker, drug company plunge by double digits on weak earnings at MarketWatch -12.39%
07:21AM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
07:07AM  Q2 2014 Durata Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Durata Therapeutics Reports Second Quarter 2014 Financial Results GlobeNewswire
Aug-06-14 08:30AM  Durata Therapeutics to Present at Upcoming Investor Conference GlobeNewswire
Aug-05-14 07:04AM  Durata Therapeutics (DRTX) Worth Watching: Stock Gains 18.5% Zacks
Aug-01-14 10:36AM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
08:43AM  The Zacks Analyst Blog Highlights: AbbVie, Shire, ARIAD Pharmaceuticals, ImmunoGen and Durata Therapeutics Zacks
Jul-31-14 08:30AM  Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014 GlobeNewswire
Jul-30-14 08:30AM  Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey GlobeNewswire
07:08AM  United Therapeutics (UTHR) Jumps: Stock Adds 8.1% in Session Zacks
Jul-18-14 08:00AM  Durata Therapeutics Announces the U.S. Launch of DALVANCE(TM) GlobeNewswire
Jun-20-14 06:04PM  FDA approves Cubist antibiotic for skin infections AP
Jun-17-14 09:00AM  Durata Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
07:54AM  Once-Weekly Vancomycin Challengers: Back To Nature 50 Years Later at Forbes
Jun-13-14 01:59PM  Durata Therapeutics CEO buys 3,000 shares at theflyonthewall.com
01:59PM  Durata Therapeutics CEO buys 3,00 shares at theflyonthewall.com
10:43AM  3 Reasons Why Shorts Are Moving into Durata Therapeutics at Motley Fool
Jun-04-14 05:00PM  New England Journal of Medicine Publishes Data From Durata Therapeutics' Discover Program GlobeNewswire
Jun-02-14 04:14PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
May-28-14 07:45PM  3 Stocks to Get on Your Watchlist at Motley Fool
May-27-14 03:47PM  Orexigen Will Run: Here's Why at Seeking Alpha -10.89%
03:30PM  Durata Therapeutics' Skin Drug Gets FDA Nod Zacks
02:07PM  Why Durata Therapeutics Inc. Shares Tumbled at Motley Fool
11:15AM  High option volume stocks: at theflyonthewall.com
10:00AM  Durata Therapeutics falls 12.1% at theflyonthewall.com
09:26AM  Tuesdays Top Health Care Stories: BioCryst, Durata, Bristol-Myers Squibb, and Incyte at Motley Fool
09:14AM  Pilgrim's Pride pursues Hillshire; Pfizer ends pursuit of AstraZeneca; Sony PlayStation heads to China Hot Stock Minute
09:00AM  Durata can carve out lucrative niche with Dalvance, says Janney Capital at theflyonthewall.com
09:00AM  Durata Therapeutics falls 7.6% at theflyonthewall.com
07:58AM  Pilgrim's Pride bids for Hillshire; Pfizer finished with AstraZeneca; Median CEO pay rises above $10M Hot Stock Minute
May-26-14 08:00AM  Stocks to watch Tuesday: AutoZone, Workday at MarketWatch
May-23-14 04:21PM  Durata Therapeutics confirms FDA approval of Dalvance at theflyonthewall.com +5.50%
04:17PM  FDA Approves Durata Therapeutics' DALVANCE(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Susceptible Gram-Positive Bacteria, Including MRSA, in Adults GlobeNewswire
04:13PM  [$$] FDA Approves Durata's Dalvance at The Wall Street Journal
03:48PM  FDA approves Dalvance to treat skin infections at theflyonthewall.com
03:24PM  Durata Therapeutics trading halted, pending news at theflyonthewall.com
05:48AM  Durata Therapeutics initiated with a Buy at MLV & Co. at theflyonthewall.com
May-21-14 05:12PM  DURATA THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
May-16-14 11:08AM  What's Next For Durata? at Seeking Alpha
May-13-14 04:30PM  Durata Therapeutics Presents Six Dalbavancin Posters at the 24th Annual ECCMID Meeting GlobeNewswire
10:43AM  Durata (DRTX) is in Overbought Territory: What's Next? Zacks
May-12-14 11:30AM  Durata Therapeutics management to meet with Summer Street at theflyonthewall.com +9.24%
Durata Therapeutics, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Its principal product includes dalbavancin, an intravenous antibiotic product candidate, which has completed Phase 3 clinical trials for the treatment of patients with acute bacterial skin and skin structure infections. The company was founded in 2009 and is headquartered in Chicago, Illinois. As of November 17, 2014, Durata Therapeutics, Inc. operates as a subsidiary of Actavis W.C. Holding Inc.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Canaan VIII LPDirectorAug 26Option Exercise2.085,03410,4715,034Nov 19 05:33 PM
Ahrens Brenton KarlDirectorAug 26Option Exercise2.085,03410,4715,034Nov 19 05:30 PM
Shannon John Patrick JrChief Commercial OfficerAug 12Buy13.723,00041,16011,000Aug 13 05:13 PM
Edick Paul RChief Executive OfficerJun 12Buy15.233,00045,69045,636Jun 13 01:53 PM
DE SCHUTTER RICHARD UDirectorMay 12Buy15.5715,000233,50515,000May 14 05:53 PM
AISLING CAPITAL III LP10% OwnerMar 21Sale15.572,64941,2553,030,175Mar 21 08:08 PM
AISLING CAPITAL III LP10% OwnerMar 20Sale15.7498,0001,542,5893,032,824Mar 21 08:08 PM